Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients With APS-1

    December 2023 in “ Journal of clinical immunology
    Romain Lévy, A. Escudier, Paul Bastard, Coralie Briand, Laura Polivka, Athanasia Stoupa, Cécile Talbotec, Anya Rothenbühler, Marina Charbit, Dominique Debray, Christine Bodemer, Jean‐Laurent Casanova, Agnès Linglart, Bénédicte Neven
    Image
    Studysummary This study describes the positive effects of the JAK inhibitor ruxolitinib in treating autoimmune manifestations in three patients with autoimmune polyendocrine syndrome type-1 over a period of at least 30 months, with excellent tolerance and no adverse events observed.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →